Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) generates news primarily around its cardiovascular drug programs, regulatory milestones, and corporate developments. The company’s lead product, CARDAMYST™ (etripamil) nasal spray, is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, and many of its announcements relate to this therapy and the broader etripamil clinical program.
News items for MIST often cover regulatory events, such as U.S. Food and Drug Administration actions on CARDAMYST, responses to Complete Response Letters, Prescription Drug User Fee Act (PDUFA) dates, and acceptance of a Marketing Authorization Application by the European Medicines Agency for etripamil nasal spray with the conditionally approved brand name TACHYMIST™ in Europe. These updates provide context on how the company’s PSVT program is progressing in major regulatory jurisdictions.
Another frequent category is clinical and scientific data. Milestone issues press releases on new analyses from its etripamil trials in PSVT and AFib-RVR, including pooled efficacy and safety results presented at medical meetings such as the American Heart Association Scientific Sessions. These articles describe conversion rates to sinus rhythm, time to conversion, and safety findings across randomized and open-label studies.
Investors and followers of MIST will also see corporate and financial news, including quarterly financial results, equity offerings, royalty purchase agreements, and inducement option grants under Nasdaq Listing Rule 5635(c)(4). Such releases outline how the company funds development and commercialization activities and how it prepares for the launch and distribution of CARDAMYST.
This news page aggregates these types of updates so readers can track Milestone’s regulatory progress, clinical data disclosures, and financing events in one place. Users interested in MIST can review past and recent headlines to understand how the company’s cardiovascular portfolio and commercial plans are evolving over time.
Milestone Pharmaceuticals has announced significant progress in the development of etripamil, an investigational treatment for paroxysmal supraventricular tachycardia (PSVT). The completion of NODE-303 and RAPID-extension studies paves the way for a New Drug Application (NDA) submission expected in Q3 2023, following positive feedback from the FDA. Etripamil aims to be the first fast-acting, patient-administered therapy for PSVT, potentially reducing reliance on emergency services. Recent Phase 3 trial results show 64.3% of patients converted to sinus rhythm within 30 minutes of self-administering etripamil, significantly higher than placebo (31.2%).
On February 28, 2023, Milestone Pharmaceuticals (Nasdaq: MIST) announced its management team will present at two upcoming investor conferences. The events include the Cowen 43rd Annual Health Care Conference on March 7 at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 2:40 p.m. ET. Live webcasts of the presentations can be accessed on Milestone's website, with archived replays available for approximately 90 days. Milestone focuses on cardiovascular medicines, with its lead candidate, etripamil, having completed Phase 3 trials for paroxysmal supraventricular tachycardia and a Phase 2 trial for atrial fibrillation.
Milestone Pharmaceuticals (Nasdaq: MIST) will host a virtual deep-dive event on December 6, 2022 at 1:00 p.m. ET to discuss the commercial prospects of etripamil, its lead investigational product for treating paroxysmal supraventricular tachycardia (PSVT). This condition affects around two million Americans and is characterized by sudden episodes of rapid heartbeat. Etripamil is a self-administered nasal spray aimed at improving treatment accessibility, shifting care from emergency settings. For more information, visit Milestone's website.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical firm dedicated to cardiovascular medicine, announced management participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. ET in New York, NY. Investors can access a live webcast via Milestone's website, with an archived replay available for 90 days post-event. Milestone's lead product, etripamil, is in Phase 3 trials for treating paroxysmal supraventricular tachycardia and Phase 2 for atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals reported significant progress with its lead product, etripamil, in treating paroxysmal supraventricular tachycardia (PSVT). The Phase 3 RAPID trial achieved its primary efficacy endpoint with 64.3% of patients converting to sinus rhythm compared to 31.2% on placebo. Safety data remains consistent with previous studies. The company plans to submit a New Drug Application to the FDA in mid-2023. Financially, Milestone had $77.2 million in cash and reported an operating loss of $14.6 million for Q3 2022, slightly higher than the prior year.
Milestone Pharmaceuticals (MIST) reported positive results from its Phase 3 RAPID trial of etripamil, a nasal spray for paroxysmal supraventricular tachycardia (PSVT). The trial achieved its primary endpoint, with 64.3% of etripamil patients converting to sinus rhythm within 30 minutes compared to 31.2% with placebo (HR = 2.62, p<0.001). Median conversion time was 17 minutes for etripamil users. Additionally, fewer medical interventions and emergency visits were noted. Safety data supported its self-administration potential. Milestone plans to submit a New Drug Application for etripamil in mid-2023.
Milestone Pharmaceuticals (Nasdaq: MIST) has announced a late-breaking presentation of data from the Phase 3 RAPID clinical trial focusing on etripamil for paroxysmal supraventricular tachycardia (PSVT). This presentation will occur at the American Heart Association Scientific Sessions 2022 from November 5-7, 2022. The trial data highlights etripamil's potential as a self-administered treatment, aiming to enhance patient convenience by shifting care from emergency settings to home use.
Milestone Pharmaceuticals (Nasdaq: MIST) announced successful results from the Phase 3 RAPID trial of etripamil, a nasal spray for treating paroxysmal supraventricular tachycardia (PSVT). The trial achieved its primary endpoint, with 64.3% of patients converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001). Safety data indicated tolerability, with no serious adverse events reported. Milestone plans to file a New Drug Application (NDA) with the U.S. FDA in mid-2023, further supporting the potential for etripamil as a self-administered treatment.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that CEO Joseph Oliveto will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 12:00 p.m. ET in New York, NY. The presentation will be accessible via live webcast on Milestone's website, with an archived replay available for 90 days. Milestone focuses on innovative cardiovascular medicines, with its lead product candidate etripamil in Phase 3 trials for paroxysmal supraventricular tachycardia and Phase 2 trials for atrial fibrillation. For more details, visit www.milestonepharma.com.
Milestone Pharmaceuticals Inc. (MIST) reported substantial progress in its Phase 3 PSVT clinical program, achieving the required 180 confirmed events for the RAPID study. The topline data readout is expected in mid-second half of 2022. Financially, the company had $86.2 million in cash as of June 30, 2022, but incurred operating losses of $16.8 million for Q2, marking a significant decline from a prior year income of $0.7 million. Research and development expenses rose to $10.7 million due to advancing clinical trials, while general and administrative costs increased to $3.9 million.